United Services Automobile Association Boosts Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV)

United Services Automobile Association boosted its stake in Roivant Sciences Ltd. (NASDAQ:ROIV) by 6.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 27,494 shares of the company’s stock after acquiring an additional 1,588 shares during the period. United Services Automobile Association’s holdings in Roivant Sciences were worth $325,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of ROIV. GAMMA Investing LLC lifted its holdings in shares of Roivant Sciences by 57.0% in the 4th quarter. GAMMA Investing LLC now owns 3,548 shares of the company’s stock valued at $42,000 after purchasing an additional 1,288 shares during the last quarter. PNC Financial Services Group Inc. increased its position in Roivant Sciences by 27.0% during the fourth quarter. PNC Financial Services Group Inc. now owns 7,079 shares of the company’s stock worth $84,000 after buying an additional 1,507 shares during the period. Victory Capital Management Inc. lifted its stake in Roivant Sciences by 6.1% in the fourth quarter. Victory Capital Management Inc. now owns 27,494 shares of the company’s stock valued at $325,000 after buying an additional 1,588 shares during the last quarter. M&T Bank Corp boosted its holdings in shares of Roivant Sciences by 16.3% in the fourth quarter. M&T Bank Corp now owns 13,194 shares of the company’s stock valued at $156,000 after acquiring an additional 1,851 shares during the period. Finally, Quarry LP grew its position in shares of Roivant Sciences by 50.0% during the third quarter. Quarry LP now owns 7,500 shares of the company’s stock worth $87,000 after acquiring an additional 2,500 shares during the last quarter. Institutional investors and hedge funds own 64.76% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently commented on the stock. Cantor Fitzgerald upgraded shares of Roivant Sciences to a “strong-buy” rating in a research report on Tuesday, March 4th. HC Wainwright reaffirmed a “buy” rating and issued a $18.00 target price on shares of Roivant Sciences in a report on Tuesday, February 11th. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Buy” and an average price target of $18.08.

Insider Activity

In related news, Director Sciences Ltd. Roivant acquired 16,845,010 shares of Roivant Sciences stock in a transaction that occurred on Monday, January 13th. The stock was purchased at an average price of $20.00 per share, for a total transaction of $336,900,200.00. Following the completion of the purchase, the director now directly owns 96,650,341 shares of the company’s stock, valued at approximately $1,933,006,820. This trade represents a 21.11 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CIO Mayukh Sukhatme sold 689,495 shares of the company’s stock in a transaction dated Thursday, December 26th. The stock was sold at an average price of $12.01, for a total transaction of $8,280,834.95. Following the transaction, the executive now owns 18,836,547 shares in the company, valued at $226,226,929.47. The trade was a 3.53 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 2,439,640 shares of company stock valued at $27,451,035 in the last three months. 7.90% of the stock is currently owned by company insiders.

Roivant Sciences Stock Performance

Shares of ROIV opened at $10.83 on Tuesday. Roivant Sciences Ltd. has a 1 year low of $9.93 and a 1 year high of $13.06. The stock has a market capitalization of $7.73 billion, a P/E ratio of -72.20 and a beta of 1.26. The company’s fifty day moving average is $10.79 and its two-hundred day moving average is $11.45.

Roivant Sciences (NASDAQ:ROIV) last posted its quarterly earnings results on Monday, February 10th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.24) by $0.04. Roivant Sciences had a negative net margin of 119.54% and a negative return on equity of 14.05%. Sell-side analysts predict that Roivant Sciences Ltd. will post -0.92 EPS for the current year.

Roivant Sciences Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.